

SynAct Pharma to participate at BIO International Convention in Boston June 16-19

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, today announced that the company will participate in the BIO International Convention in Boston, USA, June 16-19, 2025.

The BIO International Convention is the largest and most comprehensive partnering event in biotech, bringing together over 20,000 industry leaders from across the globe. The event offers a premier platform for networking, knowledge exchange, and business development within the biotech sector.

"We look forward to participating at BIO 2025 to engage with potential partners and investors, and to showcase our development programs with Resomelagon (AP1189)," said Jeppe Øvlesen, CEO of SynAct.

During the event, Synact's Chairman Anders Kronborg, Chief Business Officer James Knight, Chief Scientific Officer Thomas Jonassen and CEO Jeppe Øvlesen will be available for one-on-one meetings through the BIO partnering platform.

Read more about the BIO International Convention: <https://www.bio.org/events/bio-international-convention>

For further information, please contact:

Jeppe Øvlesen, CEO SynAct Pharma

Tel: +45 2844 7567

Email: JOO@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.

Attachments

[SynAct Pharma to participate at BIO International Convention in Boston June 16-19](#)